{"id":"simbrinza-0-2-1-ophthalmic-suspension","safety":{"commonSideEffects":[{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Taste perversion"},{"rate":null,"effect":"Allergic conjunctivitis"}]},"_chembl":{"chemblId":"CHEMBL139578","moleculeType":"Small molecule","molecularWeight":"313.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Simbrinza contains brinzolamide (carbonic anhydrase inhibitor) and brimonidine (alpha-2 adrenergic agonist). Brinzolamide inhibits carbonic anhydrase in the ciliary body, reducing aqueous humor secretion. Brimonidine stimulates alpha-2 adrenergic receptors to further decrease aqueous humor production and increase uveoscleral outflow. Together, these mechanisms lower intraocular pressure in glaucoma and ocular hypertension.","oneSentence":"Simbrinza combines a beta-adrenergic antagonist and a carbonic anhydrase inhibitor to reduce intraocular pressure by decreasing aqueous humor production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:00.287Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT04944290","phase":"PHASE3","title":"To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2021-05-28","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":447},{"nctId":"NCT04523844","phase":"NA","title":"Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections","status":"COMPLETED","sponsor":"General Hospital of Athens Elpis","startDate":"2020-05-11","conditions":"Eye Diseases, Injection Complication, Intraocular Pressure","enrollment":47},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT02770248","phase":"PHASE4","title":"24-hr Intraocular Pressure Control With SIMBRINZA ®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-05-23","conditions":"Glaucoma","enrollment":162},{"nctId":"NCT03494257","phase":"NA","title":"Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2017-09-04","conditions":"Cataract, Intraocular Pressure","enrollment":62},{"nctId":"NCT01937312","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":282},{"nctId":"NCT01937299","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":307},{"nctId":"NCT01978600","phase":"PHASE4","title":"Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Simbrinza 0.2%-1% Ophthalmic Suspension","genericName":"Simbrinza 0.2%-1% Ophthalmic Suspension","companyName":"Prairie Eye Center","companyId":"prairie-eye-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Simbrinza combines a beta-adrenergic antagonist and a carbonic anhydrase inhibitor to reduce intraocular pressure by decreasing aqueous humor production. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}